Literature DB >> 11513971

Expression and characterisation of the thrombospondin type I repeats of human properdin.

M V Perdikoulis1, U Kishore, K B Reid.   

Abstract

Properdin, an upregulator of the alternative complement pathway, is central to deposition of the activated complement fragment C3b on the surfaces of the pathogens, which it achieves by preventing the dissociation of the Bb catalytic subunit from the inherently labile C3bBb complexes. It is also known to bind sulphated glycoconjugates, such as sulphatides. Properdin has an unusual structure formed by oligomerisation of a rod-like monomer into cyclic dimers, trimers and tetramers. The monomer (approximately 53 kDa) contains an N-terminal region of no known homology, followed by six non-identical repeats of 60 amino acids (based on exon/intron boundaries), called 'thrombospondin type I repeats' or TSR modules. We have expressed and purified the N-terminal region and each of the individual TSR repeats in Escherichia coli. Although the individual recombinant TSRs, after a denaturation-renaturation cycle, appeared to be correctly folded modules, as judged by the one-dimensional (1D)- and 2D-nuclear magnetic resonance spectra of TSR3, they did not show binding to either C3b or sulphatide. Polyclonal antibodies were raised against each TSR and were found to be module-specific. The anti-TSR5 polyclonal antibody was found to inhibit binding of native human properdin to solid-phase C3b, or sulphatides. It could also block properdin-dependent haemolysis of rabbit erythrocytes. These results are consistent with the view that the TSR5 contains the major site in properdin which is involved in both C3b and sulphatide binding. It also suggests that a co-operative intramolecular interaction between TSRs, as found in the native molecule, is required for TSR5 to bind either C3b or sulphatides.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513971     DOI: 10.1016/s0167-4838(01)00238-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.

Authors:  Paula Bertram; Antonina M Akk; Hui-fang Zhou; Lynne M Mitchell; Christine T N Pham; Dennis E Hourcade
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-02

2.  Functional and structural insight into properdin control of complement alternative pathway amplification.

Authors:  Dennis V Pedersen; Lubka Roumenina; Rasmus K Jensen; Trine Af Gadeberg; Chiara Marinozzi; Capucine Picard; Tania Rybkine; Steffen Thiel; Uffe Bs Sørensen; Cordula Stover; Veronique Fremeaux-Bacchi; Gregers R Andersen
Journal:  EMBO J       Date:  2017-03-06       Impact factor: 11.598

Review 3.  Properdin: a tightly regulated critical inflammatory modulator.

Authors:  Adam Z Blatt; Sabina Pathan; Viviana P Ferreira
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

4.  Properdin and factor h: opposing players on the alternative complement pathway "see-saw".

Authors:  Lubna Kouser; Munirah Abdul-Aziz; Annapurna Nayak; Cordula M Stover; Robert B Sim; Uday Kishore
Journal:  Front Immunol       Date:  2013-04-23       Impact factor: 7.561

5.  Human Properdin Opsonizes Nanoparticles and Triggers a Potent Pro-inflammatory Response by Macrophages without Involving Complement Activation.

Authors:  Lubna Kouser; Basudev Paudyal; Anuvinder Kaur; Gudrun Stenbeck; Lucy A Jones; Suhair M Abozaid; Cordula M Stover; Emmanuel Flahaut; Robert B Sim; Uday Kishore
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

6.  Human Properdin Modulates Macrophage: Mycobacterium bovis BCG Interaction via Thrombospondin Repeats 4 and 5.

Authors:  Maha Ahmed Al-Mozaini; Anthony G Tsolaki; Munirah Abdul-Aziz; Suhair M Abozaid; Mohammed N Al-Ahdal; Ansar A Pathan; Valarmathy Murugaiah; Evgeny M Makarov; Anuvinder Kaur; Robert B Sim; Uday Kishore; Lubna Kouser
Journal:  Front Immunol       Date:  2018-05-08       Impact factor: 7.561

7.  Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.

Authors:  Jin Y Chen; Neeti S Galwankar; Heather N Emch; Smrithi S Menon; Claudio Cortes; Joshua M Thurman; Samuel A Merrill; Robert A Brodsky; Viviana P Ferreira
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

8.  The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?

Authors:  Marloes A H M Michels; Elena B Volokhina; Nicole C A J van de Kar; Lambertus P W J van den Heuvel
Journal:  Pediatr Nephrol       Date:  2018-08-23       Impact factor: 3.714

Review 9.  Complement Proteins as Soluble Pattern Recognition Receptors for Pathogenic Viruses.

Authors:  Valarmathy Murugaiah; Praveen M Varghese; Nazar Beirag; Syreeta De Cordova; Robert B Sim; Uday Kishore
Journal:  Viruses       Date:  2021-05-02       Impact factor: 5.048

10.  Human Properdin Released By Infiltrating Neutrophils Can Modulate Influenza A Virus Infection.

Authors:  Praveen M Varghese; Shuvechha Mukherjee; Futwan A Al-Mohanna; Souad M Saleh; Fahad N Almajhdi; Nazar Beirag; Saad H Alkahtani; Reena Rajkumari; Beatrice Nal Rogier; Robert B Sim; Susan Idicula-Thomas; Taruna Madan; Valarmathy Murugaiah; Uday Kishore
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.